Oculis Holding AG (NASDAQ:OCSAW – Get Free Report) was the recipient of a significant growth in short interest during the month of July. As of July 31st, there was short interest totaling 10,370 shares, a growth of 203.9% from the July 15th total of 3,412 shares. Based on an average daily trading volume, of 3,070 shares, the days-to-cover ratio is presently 3.4 days.
Oculis Stock Performance
Shares of OCSAW remained flat at $5.00 during mid-day trading on Friday. Oculis has a 1 year low of $3.63 and a 1 year high of $22.64. The business’s 50-day moving average price is $4.47 and its two-hundred day moving average price is $12.00.
Oculis Company Profile
Oculis SA is a clinical‐stage biopharmaceutical company focused on developing disease‐modifying therapies for serious eye diseases. Utilizing its proprietary ocular formulation technologies, the company is advancing a pipeline of small‐molecule product candidates designed for topical or injectable delivery. Lead programs include OCS-01, a topical eye drop candidate for diabetic macular edema, and OCS-02, targeting diabetic retinopathy. Oculis also has OCS-05 in development for optic neuropathies and other retinal disorders, reflecting its commitment to addressing a broad spectrum of unmet needs in ophthalmology.
Founded in 2016 and headquartered in Geneva, Switzerland, Oculis operates research and development facilities in Europe and the United States.
Featured Stories
- Five stocks we like better than Oculis
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.
